Invention Grant
- Patent Title: Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways
-
Application No.: US16349580Application Date: 2017-11-14
-
Publication No.: US11028084B2Publication Date: 2021-06-08
- Inventor: Claus Scheidereit , Michael Willenbrock , Peter Lindemann , Silke Radetzki , Jens-Peter Von Kries , Marc Nazare
- Applicant: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft , Forschungsverbund Berlin e.V.
- Applicant Address: DE Berlin; DE Berlin
- Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft,Forschungsverbund Berlin e.V.
- Current Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft,Forschungsverbund Berlin e.V.
- Current Assignee Address: DE Berlin; DE Berlin
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: EP16198731 20161114
- International Application: PCT/EP2017/079181 WO 20171114
- International Announcement: WO2018/087389 WO 20180517
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61P35/00 ; C07D209/56 ; C07D221/06 ; C07D471/14 ; C07D487/04 ; C07D471/16
Abstract:
A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.
Public/Granted literature
- US20190276452A1 SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS Public/Granted day:2019-09-12
Information query
